Alcobra Ltd. (NASDAQ:ADHD) has been assigned a consensus recommendation of “Hold” from the eleven research firms that are covering the company. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $3.59.

A number of equities analysts recently issued reports on ADHD shares. Roth Capital set a $8.00 price target on Alcobra and gave the company a “buy” rating in a report on Saturday, October 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $16.00 price objective on shares of Alcobra in a research note on Thursday, September 29th. Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Alcobra in a research note on Thursday, September 1st. Jefferies Group reiterated a “buy” rating on shares of Alcobra in a research note on Thursday, August 25th. Finally, Zacks Investment Research upgraded Alcobra from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research note on Tuesday, November 1st.

Shares of Alcobra (NASDAQ:ADHD) opened at 1.94 on Monday. Alcobra has a 1-year low of $1.77 and a 1-year high of $6.80. The company has a 50-day moving average of $2.52 and a 200-day moving average of $4.09. The firm’s market cap is $53.47 million.

Alcobra (NASDAQ:ADHD) last announced its quarterly earnings results on Tuesday, August 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.01. Analysts predict that Alcobra will post ($0.93) earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the company. KCG Holdings Inc. bought a new stake in Alcobra during the third quarter valued at approximately $117,000. Stifel Financial Corp boosted its position in Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock valued at $278,000 after buying an additional 15,800 shares during the last quarter. Palo Alto Investors LLC boosted its position in Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock valued at $1,225,000 after buying an additional 18,600 shares during the last quarter. VHCP Management LLC boosted its position in Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock valued at $2,799,000 after buying an additional 138,813 shares during the last quarter. Finally, VHCP Management II LLC boosted its position in Alcobra by 28.7% in the second quarter. VHCP Management II LLC now owns 1,454,402 shares of the company’s stock valued at $6,530,000 after buying an additional 323,902 shares during the last quarter. Institutional investors and hedge funds own 73.62% of the company’s stock.

Alcobra Company Profile

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

5 Day Chart for NASDAQ:ADHD

Receive News & Stock Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related stocks with our FREE daily email newsletter.